HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference taking place from September 8-10, 2025 in New York. Fireside Chat Details: ...

Core Insights - Marker Therapeutics, Inc. announced a collaboration with Cellipont Bioservices for the cGMP manufacturing of MT-601, a leading MAR-T cell therapy aimed at treating hematological malignancies and solid tumors [1][3] Company Overview - Marker Therapeutics is a clinical-stage immuno-oncology company based in Houston, TX, focusing on next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [6] - The company has conducted clinical trials involving over 200 patients, demonstrating that its autologous and allogeneic MAR-T cell products are well tolerated and show durable clinical responses [6] Clinical Development - MT-601 is currently in the Phase 1 APOLLO study targeting patients with lymphoma who have relapsed after anti-CD19 CAR-T cell therapy or are ineligible for it, with a reported 78% objective response rate and 44.4% complete response rate among participants [2] - The collaboration with Cellipont aims to support the scale-up and production of MT-601, facilitating clinical supply and potential pivotal trials [3][4] Manufacturing Partnership - Cellipont Bioservices will provide technology transfer and cGMP manufacturing services to Marker Therapeutics, leveraging its state-of-the-art facility designed for high-quality cell therapy production [3][4] - The partnership is expected to enhance the clinical development and future commercial production capabilities for MT-601 [4][5] Strategic Importance - The collaboration is viewed as a critical step for Marker Therapeutics in preparing for potential pivotal trials, particularly for patients with diffuse large B-cell lymphoma [4] - Both companies emphasize a shared commitment to quality and innovation in advancing next-generation immunotherapies [5]

Core Insights - Marker Therapeutics, Inc. is participating in Canaccord Genuity's Horizons in Oncology Virtual Conference, focusing on innovations in T cell-based immunotherapies for cancer treatment [1][2]. Company Overview - Marker Therapeutics is a clinical-stage immuno-oncology company based in Houston, TX, specializing in next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [5]. - The company was founded at Baylor College of Medicine and has conducted clinical trials involving over 200 patients, demonstrating that its autologous and allogeneic MAR-T cell products are well tolerated and show durable clinical responses [5]. - The company aims to introduce novel T cell therapies to the market while prioritizing financial resource preservation and operational excellence [5]. Panel Discussion Details - Dr. Juan Vera, CEO of Marker Therapeutics, will participate in a panel titled "CAR-T in Solid Tumors and New T-cell Approaches – Breakthroughs Ahead?" on April 7, 2025, from 11:00 AM to 11:50 AM ET [3]. - The panel will include discussions on the future of CAR-T therapies and other novel approaches in treating solid tumors [2][3]. Technology and Innovation - Marker Therapeutics is advancing a unique multi antigen recognizing (MAR)-T cell therapy platform designed to target multiple tumor-associated antigens simultaneously, showing promising clinical results in both hematologic malignancies and solid tumors [3].